NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Nasus Pharma Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$3.21+0.02 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | Before market open | – | – | – |
Press releases
Announcements Nasus Pharma filed with the SEC
AND SPECIAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
EX-99.3 to Form 6-K
Pharma Announces Transition of Chief Financial Officer
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
AND RESTATED ARTICLES OF ASSOCIATION
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Nasus Pharma Announces Closing of $15.0 Million
EX-99.1 to Form 6-K
Pharma Announces Pricing of $15.0 Million Private Placement
EX-99.1 to Form 6-K
BE HELD ON MARCH 5, 2026
EX-99.2 to Form 6-K
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF
EX-99.3 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
Pharma CEO Issues 2025 Letter to Shareholders
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Pharma Announces Closing of Initial Public Offering
EX-99.1 to Form 6-K